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Nanotechnology is a buzzword of this millennium and it has
transformed the face of research in science and technology.
The advent of nanotechnology has also inﬂuenced the
biomedical and pharmaceutical research since last decade.
Various nano-architectures have been designed for improv-
ing the therapeutic performance of drugs, proteins, peptides,
and genes and to achieve their targeting at the site of ac-
tion. Although nanotechnology has demonstrated dramatic
potential in drug delivery research, like any technology, its
real success depends on the ability of drug delivery scientists
totranslateandscaleinnovationstothecommercialpharma-
ceutical products. It is indeed a very challenging task to suc-
cessfully overcome manufacturing, clinical, and regulatory
hurdles associated with a nanotech product. Nevertheless,
the pharmaceutical industry has witnessed commercializa-
tion of the nanotechnology-based products for various ap-
plications. In the present special issue, we have tried to
consolidate various aspects of existing and upcoming nan-
otechnologies for drug delivery.
Contribution by V. Morigi et al. takes an overview of
businesspotentialandmarkettrendofpharmaceuticalnano-
technology. The authors have also discussed ﬁnancial aspects
of nanotechnology by citing noteworthy examples of few
nanotech products that have already been commercialized.
This contribution could be useful to scientists aiming to start
up nanotechnological business ventures. Contribution by N.
Anton et al. demonstrates how nanotechnology can change
the face of conventional drug delivery systems. In this
interesting investigation, the authors demonstrate that coat-
ing of conventional tablets with lipid nanoemulsion can be
used to modulate the release of the drug from tablet matrix.
The paper by P. Severino et al. gives an account of potential
of solid lipid nanocarriers for the oral delivery of drugs and
peptides. The authors have provided information about the
lipids that can be used for oral delivery, role of lipids in the
oral delivery, toxicological aspects of lipid nanocarriers, and
products under clinical development.
S. Banerjee et al. have given a complete overview of poly-
ethylene-glycol- (PEG-) based conjugates for drug delivery.
Thecontributionfostersunderstandingdesignaspectsofand
chemistry behind PEG-based nano-architectures for drug
delivery. Furthermore, the paper has a detailed discussion on
the various PEG-conjugates available in the pharmaceutical
market. Contribution by A. Garcia et al. highlights the
potential of particle replication in nonwetting templates
(PRINT), a platform technology based on lithographic tech-
niques for drug delivery applications. The contribution
clearly demonstrates potential of PRINT technology to ge-
nerate particles of various, but precise, morphology for a
variety of drugs and biotechnology-based therapeutics (pro-
teins and siRNA). The application of PRINT technology for
generating aerosols for pulmonary applications has also
been described. This contribution is an example of the at-
tributes required from a nanofabrication technique to cir-
cumventmanufacturing-relatedissuesinpharmaceuticalna-
notechnology.2 Journal of Drug Delivery
The paper by F. Lallemand et al. delineates various as-
pects of and challenges in ocular drug delivery and systema-
tically describes development of Novasorb, a cationic nano-
emulsion-based platform ocular delivery system. The au-
thors have furnished a detailed description of the formu-
lation development aspects and ocular safety of excipients
whichisfollowedbyinvivoproof-of-conceptandclinicalde-
velopment. This paper gives clear insight into various chal-
lengesfacedfordevelopingnanomedicineforoculardelivery.
The paper by J. D. Heidel and T. Schleup throws light on
the various applications of self-assembled nanocarriers con-
sisting of cyclodextrin based polymers. The authors describe
various developmental aspects of two platforms based on cy-
clodextrin-based polymers (Cyclosert and RONDEL) which
can enable eﬃcient delivery of drugs or nucleic-acid-based
therapeutics. The translational aspects of both the na-
nocarriers and in vivo proof-of-concept have also been fur-
nished in this paper. The research paper by J. Rios-Doria
et al. gives insight into developmental aspects of a pH sensi-
tivecross-linkedpolymericmicelletechnology(IVECT).The
authors describe synthesis of the polymeric micelles, their
ability to encapsulate various drugs, and in vivo proof-
of-concept for anticancer drugs like daunorubicin and
BB4007431.
In a nutshell, we believe that this special issue would give
readers insight into various aspects involved in translating
nanotechnology from bench to pharmaceutical market.
Moreover, the special issue also includes some contributions
about nanotechnologies that are currently under clinical de-
velopment.
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